Patent · US Active

Modified antigens

US9200044B2 · kind B2 · utility

1Cited by

22References

25Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Normand Blais · Laval, CA
Anne-Marie Gelinas · Laval, CA
James Raymond Brown · Berwyn, US
Dennis Murphy · Collegeville, US
Pascal Mettens · Rixensart, BE

Key dates

Filing date	Dec 2, 2014
Grant date	Dec 1, 2015
Priority date	—
Expiry date	Dec 2, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.